Comprehensive research of the pathogenesis of malignant lymphoma has resulted in the introduction of some novel concepts of treatment strategy. The cell of origin (COO) of diffuse large B cell lymphoma (DLBCL) can be identified using gene expression profiling and then becomes the most critical indicator of DLBCL. The stratification by COO is essential when incorporating molecule-targeting agents into DLBCL treatment. The era of tumor immunity has arrived. Lately, immune checkpoint inhibitors, adoptive cell immunotherapy, and other immune therapies have been transforming the management of malignant lymphoma. Now bench and bed have been getting engaged in the field of lymphoma.
"},{"@language":"ja","@value":"臨床的および分子生物学的側面から悪性リンパ腫の病態解析は進んでいる。詳細な病態解析データに基づいた治療法が開発されてきた。びまん性大細胞型B細胞リンパ腫（DLBCL）のcell of originの解析は，予後予測だけでなく，分子標的療法薬を治療法に組み入れる戦略の開発につながっている。腫瘍免疫の詳細が明らかになることにより免疫チェックポイント阻害薬，CART療法の開発が進み，悪性リンパ腫の有望な治療法であることが示された。治療反応性を高精度で診断を応用したresponse adapted treatment strategyの評価も行われている。病態研究の成果が診療に還元されつつある。
"}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1410572174036907136","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000396109452"}],"foaf:name":[{"@language":"ja","@value":"永井 宏和"},{"@language":"en","@value":"NAGAI Hirokazu"}],"jpcoar:affiliationName":[{"@language":"en","@value":"National Hospital Organization Nagoya Medical Center"},{"@language":"ja","@value":"国立病院機構名古屋医療センター"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"04851439"},{"@type":"LISSN","@value":"04851439"},{"@type":"EISSN","@value":"18820824"},{"@type":"NDL_BIB_ID","@value":"000000024253"},{"@type":"ISSN","@value":"04851439"},{"@type":"NCID","@value":"AN00252940"}],"prism:publicationName":[{"@language":"en","@value":"Rinsho Ketsueki"},{"@language":"ja","@value":"臨床血液"},{"@language":"en","@value":"Rinsho Ketsueki"},{"@language":"en","@value":"Jpn. J. Clin. Hematol."},{"@language":"en","@value":"The Japanese Journal of Clinical Hematology"},{"@language":"ja","@value":"臨床血液"}],"dc:publisher":[{"@language":"en","@value":"The Japanese Society of Hematology"},{"@language":"ja","@value":"一般社団法人 日本血液学会"}],"prism:publicationDate":"2018","prism:volume":"59","prism:number":"5","prism:startingPage":"521","prism:endingPage":"528"},"url":[{"@id":"http://id.ndl.go.jp/bib/029096277"},{"@id":"https://ndlsearch.ndl.go.jp/books/R000000004-I029096277"},{"@id":"https://search.jamas.or.jp/link/ui/2018309609"}],"availableAt":"2018","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Cell%20of%20origin","dc:title":"Cell of origin"},{"@id":"https://cir.nii.ac.jp/all?q=Immune%20checkpoint%20inhibitor","dc:title":"Immune checkpoint inhibitor"},{"@id":"https://cir.nii.ac.jp/all?q=Adoptive%20cell%20immunotherapy","dc:title":"Adoptive cell immunotherapy"},{"@id":"https://cir.nii.ac.jp/all?q=Cell%20of%20origin","dc:title":"Cell of origin"},{"@id":"https://cir.nii.ac.jp/all?q=Immune%20checkpoint%20inhibitor","dc:title":"Immune checkpoint inhibitor"},{"@id":"https://cir.nii.ac.jp/all?q=Adoptive%20cell%20immunotherapy","dc:title":"Adoptive cell immunotherapy"}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:2004285789"},{"@type":"NDL_SEARCH","@value":"oai:ndlsearch.ndl.go.jp:R000000004-I029096277"},{"@type":"PUBMED","@value":"29877242"},{"@type":"CIA","@value":"130007384551"}]}